Institute Of Hematology & Blood Diseases Hospital, China
Clinical trials sponsored by Institute Of Hematology & Blood Diseases Hospital, China, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New triple therapy aims to tackle tough leukemia mutation Results expected Sep 2026 (estimated)
- Double attack on tough myeloma: stem cell transplant plus CAR-T cells Results expected Sep 2026 (estimated)
- Promising Three-Drug cocktail targets tough leukemia mutation Results expected Oct 2026 (estimated)
- Can a new drug stop bleeding in acquired hemophilia a? Results expected Oct 2026 (estimated)
- New CAR-T therapy targets Hard-to-Treat myeloma Results expected Oct 2026 (estimated)
-
Experimental cell therapy targets stubborn leukemia in early trial
Disease control Stopped earlyThis early-phase study tested a new treatment called LCAR-AMDR cells in 4 people with acute myeloid leukemia that had come back or not responded to standard therapy. The treatment uses specially engineered immune cells to target two proteins (CLL1 and CD33) on leukemia cells. The…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental drug tested for stubborn blood disorder – but trial cut short
Disease control Stopped earlyThis early-phase study tested the drug Linperlisib in just 4 adults with autoimmune hemolytic anemia (AIHA) whose disease did not improve after at least two prior treatments. The goal was to see if the drug could help control the disease by targeting a key immune pathway. However…
Phase 1 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Experimental anemia drug trial halted after only 3 patients
Disease control Stopped earlyThis study tested a low-dose chemotherapy drug (decitabine) in people with a severe type of anemia that did not improve with standard treatments. Only 3 people were enrolled before the study was stopped early. The goal was to see if the drug could improve blood cell counts and re…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New combo aims to stop leukemia return in High-Risk patients
Disease control Stopped earlyThis study tested whether combining venetoclax with either azacytidine or a DA chemotherapy regimen could prevent relapse in acute myeloid leukemia patients who still have detectable cancer cells (MRD positive) after standard treatment. The trial planned to enroll 20 adults in co…
Phase 2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Gene hunt in leukemia: what IDH mutations mean for patients
Knowledge-focused Stopped earlyThis study aimed to find how often IDH1 and IDH2 gene mutations occur in adults with acute myeloid leukemia (AML) in China, and whether those mutations affect a patient's chance of relapse or survival. Researchers planned to analyze stored leukemia samples from over 1,000 patient…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC